1. Home
  2. News
  3. Neurotech International Ltd.
  4. Completion of Patient Recruitment in NTIRTT1 Clinical Trial
More Neurotech International Ltd. news
Neurotech International Ltd.ASX: NTI

Completion of Patient Recruitment in NTIRTT1 Clinical Trial

Sep 26, 2023 at 4:23 AM EDT · Issued by Neurotech International Ltd.

Filed with ASX · Sep 26, 2023 at 4:23 AM EDT · 3 pages · English

On 6ix: 6ix.com/news/completion-of-patient-recruitment-in-ntirtt1-clinical-trial

Neurotech International Ltd. on 6ix

Story so far

  • Last Patient Completes Treatment in NTIPANS1 Clinical TrialAug 31, 2023
  • First Patient Treated in Rett Syndrome Clinical TrialAug 1, 2023
  • NTI Receives HREC Approval for Rett Syndrome Clinical TrialJul 10, 2023

Earlier from Neurotech International

  • Last Patient Completes Treatment in NTIPANS1 Clinical TrialAug 30, 2023
  • Appendix 4E & Annual ReportAug 30, 2023
  • First Patient Treated in Rett Syndrome Clinical TrialAug 1, 2023
  • NTI Receives HREC Approval for Rett Syndrome Clinical TrialJul 9, 2023
  • NTI Granted 2 Year Extension of Treatment for ASD PatientsMay 30, 2023

Later from Neurotech International

  • Phase I/II PANDAS/PANS Clinical Trial Meets Primary EndpointOct 5, 2023
  • Neurotech Receives $3.17 Million R&D Tax Incentive RefundNov 14, 2023
  • HREC Approval to Extend Phase II/III ASD Trial to AdultsDec 3, 2023
  • Phase II/III Autism Clinical Trial Completes RecruitmentDec 18, 2023
  • NTI Receives HREC Approval for Cerebral Palsy TrialJan 28, 2024
All Neurotech International news releases↗

Follow Neurotech International into a list and get an email when it puts out news.

Follow Neurotech International
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer